http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022243550-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_134e761e8dcbff4985fa1e77a9c2062e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7062a28e4451d8f07b78cd98a0e99f33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8e29124c2345b6d7773b970123e92b7 |
| publicationDate | 2022-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022243550-A1 |
| titleOfInvention | A pan-cancer classification based on fmrp pathway activity that informs differential prognosis and therapeutic responses |
| abstract | The present invention relates to methods and compositions which provide a companion diagnostic for cancer therapy. A method for identifying and stratifying a patient or group of patients with cancer as (i) being high or low for FMRP activity, (ii) having a high or low risk prognosis, and/or (iii) being a responder or non-responder to cancer therapy, and/or (iv) having high or low immune cell infiltrated tumor. |
| priorityDate | 2021-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 889.